Literature DB >> 27535052

The Antiviral Alkaloid Berberine Reduces Chikungunya Virus-Induced Mitogen-Activated Protein Kinase Signaling.

Finny S Varghese1, Bastian Thaa2, Siti Naqiah Amrun3, Diane Simarmata3, Kai Rausalu4, Tuula A Nyman5, Andres Merits4, Gerald M McInerney2, Lisa F P Ng3, Tero Ahola1.   

Abstract

Chikungunya virus (CHIKV) has infected millions of people in the tropical and subtropical regions since its reemergence in the last decade. We recently identified the nontoxic plant alkaloid berberine as an antiviral substance against CHIKV in a high-throughput screen. Here, we show that berberine is effective in multiple cell types against a variety of CHIKV strains, also at a high multiplicity of infection, consolidating the potential of berberine as an antiviral drug. We excluded any effect of this compound on virus entry or on the activity of the viral replicase. A human phosphokinase array revealed that CHIKV infection specifically activated the major mitogen-activated protein kinase (MAPK) signaling pathways extracellular signal-related kinase (ERK), p38 and c-Jun NH2-terminal kinase (JNK). Upon treatment with berberine, this virus-induced MAPK activation was markedly reduced. Subsequent analyses with specific inhibitors of these kinases indicated that the ERK and JNK signaling cascades are important for the generation of progeny virions. In contrast to specific MAPK inhibitors, berberine lowered virus-induced activation of all major MAPK pathways and resulted in a stronger reduction in viral titers. Further, we assessed the in vivo efficacy of berberine in a mouse model and measured a significant reduction of CHIKV-induced inflammatory disease. In summary, we demonstrate the efficacy of berberine as a drug against CHIKV and highlight the importance of the MAPK signaling pathways in the alphavirus infectious cycle. IMPORTANCE: Chikungunya virus (CHIKV) is a mosquito-borne virus that causes severe and persistent muscle and joint pain and has recently spread to the Americas. No licensed drug exists to counter this virus. In this study, we report that the alkaloid berberine is antiviral against different CHIKV strains and in multiple human cell lines. We demonstrate that berberine collectively reduced the virus-induced activation of cellular mitogen-activated protein kinase signaling. The relevance of these signaling cascades in the viral life cycle was emphasized by specific inhibitors of these kinase pathways, which decreased the production of progeny virions. Berberine significantly reduced CHIKV-induced inflammatory disease in a mouse model, demonstrating efficacy of the drug in vivo Overall, this work makes a strong case for pursuing berberine as a potential anti-CHIKV therapeutic compound and for exploring the MAPK signaling pathways as antiviral targets against alphavirus infections.
Copyright © 2016, American Society for Microbiology. All Rights Reserved.

Entities:  

Mesh:

Substances:

Year:  2016        PMID: 27535052      PMCID: PMC5068526          DOI: 10.1128/JVI.01382-16

Source DB:  PubMed          Journal:  J Virol        ISSN: 0022-538X            Impact factor:   5.103


  67 in total

Review 1.  The extracellular signal-regulated kinase: multiple substrates regulate diverse cellular functions.

Authors:  Seunghee Yoon; Rony Seger
Journal:  Growth Factors       Date:  2006-03       Impact factor: 2.511

2.  Mutations in the chikungunya virus non-structural proteins cause resistance to favipiravir (T-705), a broad-spectrum antiviral.

Authors:  Leen Delang; Nidya Segura Guerrero; Ali Tas; Gilles Quérat; Boris Pastorino; Mathy Froeyen; Kai Dallmeier; Dirk Jochmans; Piet Herdewijn; Felio Bello; Eric J Snijder; Xavier de Lamballerie; Byron Martina; Johan Neyts; Martijn J van Hemert; Pieter Leyssen
Journal:  J Antimicrob Chemother       Date:  2014-06-20       Impact factor: 5.790

Review 3.  Chikungunya: Evolutionary history and recent epidemic spread.

Authors:  Scott C Weaver; Naomi L Forrester
Journal:  Antiviral Res       Date:  2015-05-12       Impact factor: 5.970

4.  Discovery of berberine, abamectin and ivermectin as antivirals against chikungunya and other alphaviruses.

Authors:  Finny S Varghese; Pasi Kaukinen; Sabine Gläsker; Maxim Bespalov; Leena Hanski; Krister Wennerberg; Beate M Kümmerer; Tero Ahola
Journal:  Antiviral Res       Date:  2016-01-02       Impact factor: 5.970

5.  Assembly of alphavirus replication complexes from RNA and protein components in a novel trans-replication system in mammalian cells.

Authors:  Pirjo Spuul; Giuseppe Balistreri; Kirsi Hellström; Andrey V Golubtsov; Eija Jokitalo; Tero Ahola
Journal:  J Virol       Date:  2011-03-09       Impact factor: 5.103

6.  Type I IFN controls chikungunya virus via its action on nonhematopoietic cells.

Authors:  Clémentine Schilte; Thérèse Couderc; Fabrice Chretien; Marion Sourisseau; Nicolas Gangneux; Florence Guivel-Benhassine; Anton Kraxner; Jürg Tschopp; Stephen Higgs; Alain Michault; Fernando Arenzana-Seisdedos; Marco Colonna; Lucie Peduto; Olivier Schwartz; Marc Lecuit; Matthew L Albert
Journal:  J Exp Med       Date:  2010-02-01       Impact factor: 14.307

7.  A reinvestigation of the multisite phosphorylation of the transcription factor c-Jun.

Authors:  Simon Morton; Roger J Davis; Ann McLaren; Philip Cohen
Journal:  EMBO J       Date:  2003-08-01       Impact factor: 11.598

8.  Acute infection of Sindbis virus induces phosphorylation and intracellular translocation of small heat shock protein HSP27 and activation of p38 MAP kinase signaling pathway.

Authors:  T Nakatsue; I Katoh; S Nakamura; Y Takahashi; Y Ikawa; Y Yoshinaka
Journal:  Biochem Biophys Res Commun       Date:  1998-12-09       Impact factor: 3.575

9.  Downregulation of cellular c-Jun N-terminal protein kinase and NF-κB activation by berberine may result in inhibition of herpes simplex virus replication.

Authors:  Siwei Song; Min Qiu; Ying Chu; Deyan Chen; Xiaohui Wang; Airong Su; Zhiwei Wu
Journal:  Antimicrob Agents Chemother       Date:  2014-06-09       Impact factor: 5.191

Review 10.  Understanding the alphaviruses: recent research on important emerging pathogens and progress towards their control.

Authors:  E A Gould; B Coutard; H Malet; B Morin; S Jamal; S Weaver; A Gorbalenya; G Moureau; C Baronti; I Delogu; N Forrester; M Khasnatinov; T Gritsun; X de Lamballerie; B Canard
Journal:  Antiviral Res       Date:  2009-07-16       Impact factor: 5.970

View more
  40 in total

1.  Design and Validation of Novel Chikungunya Virus Protease Inhibitors.

Authors:  Pratyush Kumar Das; Laura Puusepp; Finny S Varghese; Age Utt; Tero Ahola; Dzmitry G Kananovich; Margus Lopp; Andres Merits; Mati Karelson
Journal:  Antimicrob Agents Chemother       Date:  2016-11-21       Impact factor: 5.191

Review 2.  Evidence Supporting a Phased Immuno-physiological Approach to COVID-19 From Prevention Through Recovery.

Authors:  S F Yanuck; J Pizzorno; H Messier; K N Fitzgerald
Journal:  Integr Med (Encinitas)       Date:  2020

Review 3.  Vaccine and Therapeutic Options To Control Chikungunya Virus.

Authors:  Ann M Powers
Journal:  Clin Microbiol Rev       Date:  2017-12-13       Impact factor: 26.132

4.  In vitro antiviral activity of piperidine alkaloids from Senna spectabilis flowers on Chikungunya virus infection.

Authors:  Thamires Rodrigues Freitas; Raul Marques Novais; Igor Andrade Santos; Daniel Oliveira Silva Martins; Amanda Danuello; Vanderlan da Silva Bolzani; Ana Carolina Gomes Jardim; Marcos Pivatto
Journal:  Pharmacol Rep       Date:  2022-07-27       Impact factor: 3.919

5.  MBZM-N-IBT, a Novel Small Molecule, Restricts Chikungunya Virus Infection by Targeting nsP2 Protease Activity In Vitro, In Vivo, and Ex Vivo.

Authors:  Soumyajit Ghosh; Supriya Suman Keshry; Bharat Bhusan Subudhi; Soma Chattopadhyay; Saikat De; Chandan Mahish; Chinmayee Mohapatra; Ankeeta Guru; Prabhudutta Mamidi; Ankita Datey; Sweta Smita Pani; Dileep Vasudevan; Tushar Kant Beuria; Subhasis Chattopadhyay
Journal:  Antimicrob Agents Chemother       Date:  2022-06-29       Impact factor: 5.938

6.  Telmisartan Restricts Chikungunya Virus Infection In Vitro and In Vivo through the AT1/PPAR-γ/MAPKs Pathways.

Authors:  Prabhudutta Mamidi; Soumyajit Ghosh; Saikat De; Supriya Suman Keshry; Chandan Mahish; Sweta Smita Pani; Eshna Laha; Amrita Ray; Ankita Datey; Sanchari Chatterjee; Sharad Singh; Tathagata Mukherjee; Somlata Khamaru; Subhasis Chattopadhyay; Bharat Bhusan Subudhi; Soma Chattopadhyay
Journal:  Antimicrob Agents Chemother       Date:  2021-11-08       Impact factor: 5.938

7.  Beyond Members of the Flaviviridae Family, Sofosbuvir Also Inhibits Chikungunya Virus Replication.

Authors:  André C Ferreira; Patrícia A Reis; Caroline S de Freitas; Carolina Q Sacramento; Lucas Villas Bôas Hoelz; Mônica M Bastos; Mayara Mattos; Natasha Rocha; Isaclaudia Gomes de Azevedo Quintanilha; Carolina da Silva Gouveia Pedrosa; Leticia Rocha Quintino Souza; Erick Correia Loiola; Pablo Trindade; Yasmine Rangel Vieira; Giselle Barbosa-Lima; Hugo C de Castro Faria Neto; Nubia Boechat; Stevens K Rehen; Karin Brüning; Fernando A Bozza; Patrícia T Bozza; Thiago Moreno L Souza
Journal:  Antimicrob Agents Chemother       Date:  2019-01-29       Impact factor: 5.191

8.  A Chikungunya Virus trans-Replicase System Reveals the Importance of Delayed Nonstructural Polyprotein Processing for Efficient Replication Complex Formation in Mosquito Cells.

Authors:  Koen Bartholomeeusen; Age Utt; Sandra Coppens; Kai Rausalu; Katleen Vereecken; Kevin K Ariën; Andres Merits
Journal:  J Virol       Date:  2018-06-29       Impact factor: 5.103

Review 9.  Understanding Molecular Pathogenesis with Chikungunya Virus Research Tools.

Authors:  Guillaume Carissimo; Lisa F P Ng
Journal:  Curr Top Microbiol Immunol       Date:  2022       Impact factor: 4.291

Review 10.  Antiviral Activity Exerted by Natural Products against Human Viruses.

Authors:  Maria Musarra-Pizzo; Rosamaria Pennisi; Ichrak Ben-Amor; Giuseppina Mandalari; Maria Teresa Sciortino
Journal:  Viruses       Date:  2021-05-04       Impact factor: 5.048

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.